Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Analytical Method Development: Total Ash and Acid Insoluble Ash Method Development – V 2.0

Posted on By

Analytical Method Development: Total Ash and Acid Insoluble Ash Method Development – V 2.0

SOP for Total Ash and Acid Insoluble Ash Method Development in AMD Laboratory


Department Analytical Method Development
SOP No. SOP/AMD/049/2025
Supersedes SOP/AMD/049/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP defines the procedure for developing and validating analytical methods for the determination of Total Ash and Acid Insoluble Ash in APIs, excipients, and pharmaceutical formulations using ignition and hydrochloric acid treatment, as per pharmacopeial specifications.

2. Scope

This SOP is applicable to the Analytical Method Development (AMD) department for the quantitative assessment of total inorganic residue and acid-insoluble matter in raw materials and formulations, using muffle furnace techniques in accordance with IP, USP, and Ph. Eur. standards.

3. Responsibilities

  • Analytical Chemist: Carries out sample ignition, acid treatment, and records results.
  • Reviewer: Verifies calculations and confirms repeatability of method.
  • QA: Reviews validation data and ensures method compliance with compendial guidelines.
  • Head – AMD: Approves method and ensures integration into development reports and regulatory submissions.

4. Accountability

The Head of AMD is accountable for ensuring that the Total Ash and Acid Insoluble Ash methods are validated and conducted according to regulatory and pharmacopeial requirements.

See also  Analytical Method Development: Forced Degradation Studies - V 2.0

5. Procedure

5.1 Selection of Method Type

  1. Total Ash: Determines all inorganic content after igniting the sample to constant weight.
  2. Acid Insoluble Ash: Measures portion of ash that remains insoluble after treatment with dilute hydrochloric acid.
  3. Refer to IP, USP <281>, or Ph. Eur. 2.4.16 for guidance.

5.2 Equipment and Crucible Preparation

  1. Use a silica crucible cleaned, ignited, and cooled in a desiccator prior to use.
  2. Ensure muffle furnace is calibrated and certified for 600 ± 25°C operations.
  3. Record crucible tare weights in Annexure-1: Crucible Weight Record.

5.3 Total Ash Determination

  1. Accurately weigh 2–3 g of the powdered sample into the prepared crucible.
  2. Ignite slowly at first to avoid loss due to spattering. Then raise temperature gradually to 600 ± 25°C.
  3. Continue heating until a light grey or white ash is obtained (no black particles).
  4. Cool in a desiccator and weigh the residue.
  5. Repeat heating until constant weight is achieved (weight difference ≤ 0.5 mg).
  6. Calculate Total Ash (%) using:
    Total Ash (%) = (Weight of ash / Weight of sample) × 100
  7. Document results in Annexure-2: Total Ash Worksheet.

5.4 Acid Insoluble Ash Determination

  1. Add 25 mL of 2N HCl to crucible containing total ash.
  2. Cover with watch glass and gently boil for 5 minutes.
  3. Filter the mixture using ashless filter paper and hot water wash until neutral.
  4. Transfer filter paper with residue back to the crucible and ignite at 600 ± 25°C.
  5. Cool and weigh until constant mass.
  6. Calculate Acid Insoluble Ash (%) using:
    Acid Insoluble Ash (%) = (Weight of acid-insoluble residue / Weight of sample) × 100
  7. Record results in Annexure-3: Acid Insoluble Ash Worksheet.

5.5 Method Optimization

  1. Conduct method trials to evaluate:
    • Sample weight variation (1 g, 2 g, 3 g)
    • Furnace holding time (2 vs 3 hours)
    • Volume and concentration of HCl used
  2. Document findings in Annexure-4: Method Optimization Log.

5.6 Method Validation

  1. Follow ICH Q2(R1) validation guidelines:
  2. Precision: Triplicate determinations with RSD ≤ 2.0%.
  3. Accuracy: Spike samples with known mineral content and recover within 98–102%.
  4. Specificity: Ensure no interference from volatile or acid-soluble matter.
  5. Robustness: Confirm results under slight variation in ignition temperature or acid volume.
  6. Summarize in Annexure-5: Validation Summary Report.

6. Abbreviations

  • AMD: Analytical Method Development
  • RSD: Relative Standard Deviation
  • USP: United States Pharmacopeia
  • Ph. Eur.: European Pharmacopoeia
  • QA: Quality Assurance

7. Documents

  1. Crucible Weight Record – Annexure-1
  2. Total Ash Worksheet – Annexure-2
  3. Acid Insoluble Ash Worksheet – Annexure-3
  4. Method Optimization Log – Annexure-4
  5. Validation Summary Report – Annexure-5

8. References

  • USP <281> – Residue on Ignition
  • Ph. Eur. 2.4.16 – Ash Tests
  • IP 2022 – Total and Acid Insoluble Ash
  • ICH Q2(R1) – Validation of Analytical Procedures

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Crucible Weight Record

Date Crucible ID Empty Weight (g) Prepared By
03/05/2025 C-101 32.128 Meenal Patil

Annexure-2: Total Ash Worksheet

Sample Initial Weight (g) Residue Weight (g) Total Ash (%) Analyst
Excipient-X 2.000 0.046 2.30 Ajay Mehra

Annexure-3: Acid Insoluble Ash Worksheet

Sample Residue Weight (g) Insoluble Residue (g) Acid Insoluble Ash (%) Analyst
Excipient-X 0.046 0.003 0.15 Sunita Reddy

Annexure-4: Method Optimization Log

Trial Sample Size Ignition Time HCl Volume Total Ash (%) Conclusion
1 1 g 2 h 20 mL 2.78 Acceptable
2 2 g 3 h 25 mL 2.30 Optimized

Annexure-5: Validation Summary Report

Parameter Acceptance Criteria Result Status
Precision RSD ≤ 2% 1.5% Pass
Accuracy 98–102% 99.3% Pass
Robustness ±10°C variation Consistent Pass

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Included optimization data and annexure restructuring Annual Review Update
See also  Analytical Method Development: Preparation of AMD Master Plan - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Biosimilars: SOP for Audit Readiness of CLD Documentation – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version